Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 15/20 | 0.59 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | TAC3 | Q9UHF0 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | HNF4A | P41235 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22220787 | 0.87 | FASN (0.56) | FASNTACR2TACR1TAC3HPGD | |
| SCHEMBL14731379 | 0.85 | FASN (0.52) | FASNTACR2TACR1TAC3MEN1 | |
| SCHEMBL22220786 | 0.81 | FASN (0.58) | FASN | |
| SCHEMBL22220858 | 0.80 | FASN (0.56) | FASNTACR2TACR1TAC3BCHE | |
| SCHEMBL14731385 | 0.79 | FASN (0.56) | FASN | |
| SCHEMBL22220782 | 0.79 | FASN (0.70) | FASNMEN1KMT2A | |
| SCHEMBL14731380 | 0.78 | FASN (0.69) | FASN | |
| SCHEMBL22220818 | 0.77 | FASN (0.57) | FASN | |
| SCHEMBL22220857 | 0.76 | FASN (0.71) | FASN | |
| SCHEMBL22220822 | 0.75 | FASN (0.59) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | FASN 2790/4885TACR2 1620/4885TACR1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.